Q2 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: €0.815 (-1.21%)

Transcript 10-Q8-K

Key Points

Positve

Lineage Cell Therapeutics Inc (LCTX) reported positive long-term results from its phase 12A clinical trial for the Opergen program, showing a consistent and durable treatment effect over three years.
The company has a strong partnership with Roche and Genentech, providing clinical and development expertise and financial backing for trials necessary for approval.
Lineage Cell Therapeutics Inc (LCTX) has developed a GMP banking and production platform capable of generating millions of doses, enhancing its manufacturing capabilities.
The company is exploring new therapeutic areas, leveraging its directed differentiation expertise and recent manufacturing accomplishments to expand and diversify its pipeline.
Lineage Cell Therapeutics Inc (LCTX) is pursuing non-dilutive funding strategies, including grants and milestone payments, to reduce dependency on equity capital markets.

Negative

The company reported a significant increase in operating expenses, primarily due to a $14.8 million impairment expense related to an intangible asset.
Lineage Cell Therapeutics Inc (LCTX) experienced a net loss of $30.5 million for the quarter, a substantial increase compared to the same period in 2024.
There is uncertainty regarding the timing and outcome of ongoing clinical trials, as the company does not have access to data from the ongoing phase 2A trial.
The biotech market remains challenging, and the company is mindful of its cost of capital, indicating potential financial constraints.
Enrollment in clinical trials, particularly for chronic patients, is unpredictable, posing challenges for trial progression and data disclosure timelines.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LCTX.A - Lineage Cell Therapeutics Inc
Q2 2025 Lineage Cell Therapeutics Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the lineage Cell Therapeutics 2nd quarter 2025 conference call.

At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the investors section of lineage website at www.inageell.com.

This call is subject to copyright and is the property of lineage and recordings, reproductions, or transmissions of this call without the express written consent of lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ianhong, head of investor relations of Linage. Miss Hong, please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.